Management of ASCUS with Positive HPV but Negative for High-Risk Strains

Understanding ASCUS and HPV Status

The American College of Obstetricians and Gynecologists recommends that ASCUS represents approximately 4% of all cervical cytology smears and requires additional triage due to a 9.7% risk of CIN 2 or more serious abnormality in non-adolescent women 3
The management approach differs based on the specific HPV status, particularly whether high-risk HPV types are present, as stated by the National Comprehensive Cancer Network 4, 5
When HPV testing is positive but specifically negative for high-risk strains, the risk of progression to high-grade lesions is significantly lower, according to the Centers for Disease Control and Prevention 1, 2

The National Comprehensive Cancer Network recommends confirming that the HPV test is positive but specifically negative for high-risk types (16, 18, and other oncogenic types) 5, 6
Consider patient age as a factor in management decisions: for women ≥21 years, the Centers for Disease Control and Prevention recommends following the protocol below 1, 7
Repeat cytology at 12 months is the preferred approach for ASCUS with positive HPV but negative for high-risk strains, as recommended by the Centers for Disease Control and Prevention 1, 2

Low-risk HPV types have significantly lower progression rates to CIN2+ or CIN3+ compared to high-risk types (especially HPV 16/18), according to the National Comprehensive Cancer Network 5, 6
Studies show that women with non-high-risk HPV types have only about a 3% risk of developing CIN3+ compared to 14-17% for those with HPV 16/18, as reported by the National Comprehensive Cancer Network 5
The 2019 risk-based management guidelines support deferring colposcopy for patients at lower risk, according to the Centers for Disease Control and Prevention 8

Document the HPV testing methodology used, as different tests have varying sensitivities for detecting specific HPV types, as recommended by the Centers for Disease Control and Prevention 1, 2
Ensure patient understanding of the follow-up plan and importance of returning for the 12-month repeat cytology, according to the Centers for Disease Control and Prevention 7, 9

Avoid unnecessary colposcopy for ASCUS with negative high-risk HPV, as this can lead to overtreatment and unnecessary procedures, as stated by the Centers for Disease Control and Prevention 8
Don't confuse management protocols for ASCUS/HPV-positive (but negative for high-risk types) with those for ASCUS/high-risk HPV-positive, which would require immediate colposcopy, according to the National Comprehensive Cancer Network and the Centers for Disease Control and Prevention 4, 1

For pregnant women, the same management approach applies, but any invasive procedures should be deferred until after delivery unless there is suspicion for high-grade disease, as recommended by the American Academy of Family Physicians 3
For immunocompromised women, consider more aggressive follow-up with shorter intervals between cytology tests, according to the Centers for Disease Control and Prevention 1